Artificial Intelligence In Drug Discovery And Development
-
- Taschenbuch ausgewählt
- eBook
-
Sprache:Englisch
34,99 €
inkl. gesetzl. MwSt.,
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
31.05.2023
Verlag
Lekwandza MediaSeitenzahl
74
Maße (L/B/H)
21,6/14/0,5 cm
Gewicht
106 g
Sprache
Englisch
EAN
9798223379478
Artificial Intelligence (AI) represents the simulation of human intelligence processes by computer systems, and in the 21st century, it has emerged as a transformative force in the healthcare and medical sectors. By leveraging machine learning-a key subset of AI-researchers and clinicians can extract vital insights from vast datasets, enabling more accurate predictions of health outcomes and significantly enhancing clinical decision-making. One of the most revolutionary applications of AI is found within the biopharmaceutical value chain, specifically in the field of drug discovery and development. Traditionally, discovering new medications is an arduous, high-risk, and prohibitively expensive process, often spanning over a decade with high failure rates. AI addresses these challenges by analyzing complex biological data from genetics, proteomics, and other life sciences to identify promising drug candidates more efficiently. The integration of AI into the drug discovery pipeline offers several critical advantages:Cost and Time Reduction: AI streamlines research and development, lowering the financial barriers to early-stage discovery. Enhanced Safety: By predicting potential risks and side effects before drugs reach human participants, AI helps avoid traumatic events during late-stage clinical trials. Innovation Growth: There has been a surge in AI-based startups focused on drug innovation, driven by the increasing availability of sophisticated algorithms and the rising adoption of cloud-based services. Market Pressures: The impending patent expiration of various "blockbuster" drugs is pushing the industry to accelerate innovation through automated intelligence. Despite its immense potential, the field faces notable hurdles. The growth of the AI-driven healthcare market is currently restrained by a significant shortage of specialized workers, ambiguous regulatory guidelines for medical-grade software, and a lack of high-quality, standardized datasets. Overcoming these barriers will be essential for AI to fully realize its role in ushering in a new era of precision medicine and pharmaceutical efficiency.
Noch keine Bewertungen vorhanden
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.
Kurze Frage zu unserer Seite
Vielen Dank für dein Feedback
Wir nutzen dein Feedback, um unsere Produktseiten zu verbessern. Bitte habe Verständnis, dass wir dir keine Rückmeldung geben können. Falls du Kontakt mit uns aufnehmen möchtest, kannst du dich aber gerne an unseren Kund*innenservice wenden.
zum Kundenservice